Evidence map›Paper›PMID 36258757›Full record

ArticleNano research2023

Intracellular and extracellular enzymatic responsive micelle for intelligent therapy of cancer.

Dong Wan, Qinan Zhu, Jianxin Zhang, Xi Chen, Fangzhou Li, Yi Liu, Jie Pan

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Fibroblasts: invigorated targets in pre-metastatic niche formation.International journal of biological sciences · 2024
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Dong WanSchool of Chemical Engineering and Technology, Tiangong University, Tianjin, 300387 China.
Qinan ZhuSchool of Chemical Engineering and Technology, Tiangong University, Tianjin, 300387 China.
Jianxin ZhangSchool of Chemistry, Tiangong University, Tianjin, 300387 China.
Xi ChenSchool of Chemical Engineering and Technology, Tiangong University, Tianjin, 300387 China.
Fangzhou LiCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190 China.
Yi LiuSchool of Chemistry, Tiangong University, Tianjin, 300387 China.
Jie PanSchool of Chemical Engineering and Technology, Tiangong University, Tianjin, 300387 China.
Tiangong University · CNNational Center for Nanoscience and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, the incidence of cancer keeps increasing, seriously endangers human health, and has evolved into the main culprit of human death. Conventional chemotherapeutic drugs, such as paclitaxel and doxorubicin (DOX), have some disadvantages, including low therapeutic effect, poor water solubility, high toxic side effects, short blood circulation time in the body, and so on. To improve the anti-tumor effect of the drug Electronic Supplementary Material: Supplementary material () is available in the online version of this article at 10.1007/s12274-022-4967-1.

Indexed as

cancerenzyme-responsivefolatemicellepeptide

Identifiers

PMID36258757
PMCPMC9561310
OpenAlexW4306157777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.